nodes	percent_of_prediction	percent_of_DWPC	metapath
Loratadine—ABCB1—Mitomycin—urinary bladder cancer	0.164	0.256	CbGbCtD
Loratadine—CYP3A4—Thiotepa—urinary bladder cancer	0.0745	0.116	CbGbCtD
Loratadine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0597	0.0931	CbGbCtD
Loratadine—CYP2C8—Etoposide—urinary bladder cancer	0.0498	0.0777	CbGbCtD
Loratadine—ABCB1—Gemcitabine—urinary bladder cancer	0.0472	0.0736	CbGbCtD
Loratadine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0416	0.0649	CbGbCtD
Loratadine—CYP2C9—Cisplatin—urinary bladder cancer	0.0354	0.0551	CbGbCtD
Loratadine—ABCB1—Cisplatin—urinary bladder cancer	0.0343	0.0535	CbGbCtD
Loratadine—ABCB1—Etoposide—urinary bladder cancer	0.0337	0.0526	CbGbCtD
Loratadine—ABCB1—Doxorubicin—urinary bladder cancer	0.023	0.0359	CbGbCtD
Loratadine—ABCB1—Methotrexate—urinary bladder cancer	0.0223	0.0347	CbGbCtD
Loratadine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0217	0.0338	CbGbCtD
Loratadine—CYP3A4—Etoposide—urinary bladder cancer	0.0202	0.0315	CbGbCtD
Loratadine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0138	0.0215	CbGbCtD
Loratadine—CYP2C19—urine—urinary bladder cancer	0.00699	0.126	CbGeAlD
Loratadine—CYP2C9—urine—urinary bladder cancer	0.00542	0.0979	CbGeAlD
Loratadine—CYP3A4—urine—urinary bladder cancer	0.00413	0.0747	CbGeAlD
Loratadine—CYP2D6—urine—urinary bladder cancer	0.00407	0.0735	CbGeAlD
Loratadine—KCNH2—prostate gland—urinary bladder cancer	0.0024	0.0433	CbGeAlD
Loratadine—KCNH2—seminal vesicle—urinary bladder cancer	0.00203	0.0366	CbGeAlD
Loratadine—HRH1—prostate gland—urinary bladder cancer	0.00192	0.0347	CbGeAlD
Loratadine—KCNH2—renal system—urinary bladder cancer	0.00163	0.0295	CbGeAlD
Loratadine—KCNH2—urethra—urinary bladder cancer	0.0016	0.029	CbGeAlD
Loratadine—CYP2C8—renal system—urinary bladder cancer	0.00149	0.027	CbGeAlD
Loratadine—HRH1—epithelium—urinary bladder cancer	0.00141	0.0255	CbGeAlD
Loratadine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00136	0.0245	CbGeAlD
Loratadine—KCNH2—female reproductive system—urinary bladder cancer	0.00131	0.0236	CbGeAlD
Loratadine—HRH1—urethra—urinary bladder cancer	0.00129	0.0232	CbGeAlD
Loratadine—CYP2C19—vagina—urinary bladder cancer	0.00124	0.0224	CbGeAlD
Loratadine—CYP2C8—female reproductive system—urinary bladder cancer	0.0012	0.0216	CbGeAlD
Loratadine—KCNH2—vagina—urinary bladder cancer	0.00118	0.0214	CbGeAlD
Loratadine—CYP2C8—vagina—urinary bladder cancer	0.00108	0.0195	CbGeAlD
Loratadine—CYP2C9—female reproductive system—urinary bladder cancer	0.00106	0.0192	CbGeAlD
Loratadine—ABCB1—prostate gland—urinary bladder cancer	0.00105	0.019	CbGeAlD
Loratadine—HRH1—female reproductive system—urinary bladder cancer	0.00105	0.0189	CbGeAlD
Loratadine—CYP3A4—renal system—urinary bladder cancer	0.00101	0.0183	CbGeAlD
Loratadine—CYP2D6—renal system—urinary bladder cancer	0.000996	0.018	CbGeAlD
Loratadine—HRH1—vagina—urinary bladder cancer	0.000948	0.0171	CbGeAlD
Loratadine—ABCB1—seminal vesicle—urinary bladder cancer	0.000889	0.016	CbGeAlD
Loratadine—CYP3A4—female reproductive system—urinary bladder cancer	0.00081	0.0146	CbGeAlD
Loratadine—CYP2D6—female reproductive system—urinary bladder cancer	0.000797	0.0144	CbGeAlD
Loratadine—ABCB1—epithelium—urinary bladder cancer	0.000772	0.0139	CbGeAlD
Loratadine—KCNH2—lymph node—urinary bladder cancer	0.000765	0.0138	CbGeAlD
Loratadine—ABCB1—renal system—urinary bladder cancer	0.000716	0.0129	CbGeAlD
Loratadine—ABCB1—urethra—urinary bladder cancer	0.000703	0.0127	CbGeAlD
Loratadine—HRH1—lymph node—urinary bladder cancer	0.000613	0.0111	CbGeAlD
Loratadine—Myalgia—Cisplatin—urinary bladder cancer	0.000582	0.00267	CcSEcCtD
Loratadine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000582	0.00267	CcSEcCtD
Loratadine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000582	0.00267	CcSEcCtD
Loratadine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000581	0.00266	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000578	0.00265	CcSEcCtD
Loratadine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000577	0.00265	CcSEcCtD
Loratadine—Discomfort—Cisplatin—urinary bladder cancer	0.000575	0.00264	CcSEcCtD
Loratadine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000575	0.00263	CcSEcCtD
Loratadine—Increased appetite—Doxorubicin—urinary bladder cancer	0.000574	0.00263	CcSEcCtD
Loratadine—ABCB1—female reproductive system—urinary bladder cancer	0.000574	0.0104	CbGeAlD
Loratadine—Malaise—Etoposide—urinary bladder cancer	0.000565	0.00259	CcSEcCtD
Loratadine—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000565	0.00259	CcSEcCtD
Loratadine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000563	0.00258	CcSEcCtD
Loratadine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000563	0.00258	CcSEcCtD
Loratadine—Hypotension—Gemcitabine—urinary bladder cancer	0.00056	0.00256	CcSEcCtD
Loratadine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000558	0.00256	CcSEcCtD
Loratadine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000551	0.00252	CcSEcCtD
Loratadine—Lethargy—Doxorubicin—urinary bladder cancer	0.000551	0.00252	CcSEcCtD
Loratadine—Hypotension—Fluorouracil—urinary bladder cancer	0.00055	0.00252	CcSEcCtD
Loratadine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000547	0.00251	CcSEcCtD
Loratadine—Cough—Etoposide—urinary bladder cancer	0.000547	0.00251	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000546	0.0025	CcSEcCtD
Loratadine—Tachycardia—Cisplatin—urinary bladder cancer	0.000545	0.0025	CcSEcCtD
Loratadine—Skin disorder—Cisplatin—urinary bladder cancer	0.000542	0.00248	CcSEcCtD
Loratadine—Insomnia—Gemcitabine—urinary bladder cancer	0.000542	0.00248	CcSEcCtD
Loratadine—Hypertension—Etoposide—urinary bladder cancer	0.000541	0.00248	CcSEcCtD
Loratadine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000538	0.00246	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000536	0.00246	CcSEcCtD
Loratadine—Chest pain—Etoposide—urinary bladder cancer	0.000533	0.00244	CcSEcCtD
Loratadine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000533	0.00244	CcSEcCtD
Loratadine—Insomnia—Fluorouracil—urinary bladder cancer	0.000532	0.00244	CcSEcCtD
Loratadine—Somnolence—Gemcitabine—urinary bladder cancer	0.000532	0.00244	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00053	0.00243	CcSEcCtD
Loratadine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000529	0.00242	CcSEcCtD
Loratadine—Discomfort—Etoposide—urinary bladder cancer	0.000527	0.00241	CcSEcCtD
Loratadine—Somnolence—Fluorouracil—urinary bladder cancer	0.000523	0.0024	CcSEcCtD
Loratadine—Hypotension—Cisplatin—urinary bladder cancer	0.000522	0.00239	CcSEcCtD
Loratadine—ABCB1—vagina—urinary bladder cancer	0.000519	0.00937	CbGeAlD
Loratadine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000518	0.00237	CcSEcCtD
Loratadine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000517	0.00237	CcSEcCtD
Loratadine—Fatigue—Gemcitabine—urinary bladder cancer	0.000516	0.00237	CcSEcCtD
Loratadine—Gastritis—Epirubicin—urinary bladder cancer	0.000516	0.00237	CcSEcCtD
Loratadine—Constipation—Gemcitabine—urinary bladder cancer	0.000512	0.00235	CcSEcCtD
Loratadine—Pain—Gemcitabine—urinary bladder cancer	0.000512	0.00235	CcSEcCtD
Loratadine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000511	0.00234	CcSEcCtD
Loratadine—Asthenia—Thiotepa—urinary bladder cancer	0.000511	0.00234	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000508	0.00233	CcSEcCtD
Loratadine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000508	0.00233	CcSEcCtD
Loratadine—Pain—Fluorouracil—urinary bladder cancer	0.000503	0.00231	CcSEcCtD
Loratadine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000501	0.0023	CcSEcCtD
Loratadine—Tachycardia—Etoposide—urinary bladder cancer	0.000499	0.00229	CcSEcCtD
Loratadine—Skin disorder—Etoposide—urinary bladder cancer	0.000497	0.00228	CcSEcCtD
Loratadine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000493	0.00226	CcSEcCtD
Loratadine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000493	0.00226	CcSEcCtD
Loratadine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000487	0.00223	CcSEcCtD
Loratadine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000485	0.00222	CcSEcCtD
Loratadine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000482	0.00221	CcSEcCtD
Loratadine—Drowsiness—Methotrexate—urinary bladder cancer	0.00048	0.0022	CcSEcCtD
Loratadine—Depression—Methotrexate—urinary bladder cancer	0.000479	0.00219	CcSEcCtD
Loratadine—Hypotension—Etoposide—urinary bladder cancer	0.000478	0.00219	CcSEcCtD
Loratadine—Gastritis—Doxorubicin—urinary bladder cancer	0.000478	0.00219	CcSEcCtD
Loratadine—Pain—Cisplatin—urinary bladder cancer	0.000477	0.00219	CcSEcCtD
Loratadine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000473	0.00217	CcSEcCtD
Loratadine—Dizziness—Thiotepa—urinary bladder cancer	0.000471	0.00216	CcSEcCtD
Loratadine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000466	0.00213	CcSEcCtD
Loratadine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000465	0.00213	CcSEcCtD
Loratadine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00046	0.00211	CcSEcCtD
Loratadine—Paraesthesia—Etoposide—urinary bladder cancer	0.000459	0.0021	CcSEcCtD
Loratadine—Somnolence—Etoposide—urinary bladder cancer	0.000455	0.00208	CcSEcCtD
Loratadine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000454	0.00208	CcSEcCtD
Loratadine—Epistaxis—Methotrexate—urinary bladder cancer	0.000453	0.00208	CcSEcCtD
Loratadine—Vomiting—Thiotepa—urinary bladder cancer	0.000453	0.00207	CcSEcCtD
Loratadine—Drowsiness—Epirubicin—urinary bladder cancer	0.000449	0.00206	CcSEcCtD
Loratadine—Rash—Thiotepa—urinary bladder cancer	0.000449	0.00206	CcSEcCtD
Loratadine—Dermatitis—Thiotepa—urinary bladder cancer	0.000448	0.00205	CcSEcCtD
Loratadine—Headache—Thiotepa—urinary bladder cancer	0.000446	0.00204	CcSEcCtD
Loratadine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000441	0.00202	CcSEcCtD
Loratadine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000441	0.00202	CcSEcCtD
Loratadine—Fatigue—Etoposide—urinary bladder cancer	0.000441	0.00202	CcSEcCtD
Loratadine—Pain—Etoposide—urinary bladder cancer	0.000437	0.002	CcSEcCtD
Loratadine—Constipation—Etoposide—urinary bladder cancer	0.000437	0.002	CcSEcCtD
Loratadine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000431	0.00197	CcSEcCtD
Loratadine—Asthenia—Gemcitabine—urinary bladder cancer	0.00043	0.00197	CcSEcCtD
Loratadine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000428	0.00196	CcSEcCtD
Loratadine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000425	0.00195	CcSEcCtD
Loratadine—Epistaxis—Epirubicin—urinary bladder cancer	0.000424	0.00194	CcSEcCtD
Loratadine—Nausea—Thiotepa—urinary bladder cancer	0.000423	0.00194	CcSEcCtD
Loratadine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000421	0.00193	CcSEcCtD
Loratadine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000418	0.00192	CcSEcCtD
Loratadine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000416	0.00191	CcSEcCtD
Loratadine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00041	0.00188	CcSEcCtD
Loratadine—Abdominal pain—Etoposide—urinary bladder cancer	0.000404	0.00185	CcSEcCtD
Loratadine—Body temperature increased—Etoposide—urinary bladder cancer	0.000404	0.00185	CcSEcCtD
Loratadine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000403	0.00185	CcSEcCtD
Loratadine—Tinnitus—Methotrexate—urinary bladder cancer	0.000402	0.00184	CcSEcCtD
Loratadine—Asthenia—Cisplatin—urinary bladder cancer	0.0004	0.00184	CcSEcCtD
Loratadine—Pharyngitis—Epirubicin—urinary bladder cancer	0.0004	0.00183	CcSEcCtD
Loratadine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000393	0.0018	CcSEcCtD
Loratadine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000392	0.0018	CcSEcCtD
Loratadine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000389	0.00178	CcSEcCtD
Loratadine—Dizziness—Fluorouracil—urinary bladder cancer	0.000389	0.00178	CcSEcCtD
Loratadine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000382	0.00175	CcSEcCtD
Loratadine—Alopecia—Methotrexate—urinary bladder cancer	0.000381	0.00175	CcSEcCtD
Loratadine—Vomiting—Gemcitabine—urinary bladder cancer	0.000381	0.00174	CcSEcCtD
Loratadine—Rash—Gemcitabine—urinary bladder cancer	0.000378	0.00173	CcSEcCtD
Loratadine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000377	0.00173	CcSEcCtD
Loratadine—Tinnitus—Epirubicin—urinary bladder cancer	0.000376	0.00172	CcSEcCtD
Loratadine—Headache—Gemcitabine—urinary bladder cancer	0.000375	0.00172	CcSEcCtD
Loratadine—Vomiting—Fluorouracil—urinary bladder cancer	0.000374	0.00172	CcSEcCtD
Loratadine—Rash—Fluorouracil—urinary bladder cancer	0.000371	0.0017	CcSEcCtD
Loratadine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000371	0.0017	CcSEcCtD
Loratadine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00037	0.0017	CcSEcCtD
Loratadine—Headache—Fluorouracil—urinary bladder cancer	0.000369	0.00169	CcSEcCtD
Loratadine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000367	0.00168	CcSEcCtD
Loratadine—Asthenia—Etoposide—urinary bladder cancer	0.000367	0.00168	CcSEcCtD
Loratadine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000364	0.00167	CcSEcCtD
Loratadine—Arrhythmia—Epirubicin—urinary bladder cancer	0.00036	0.00165	CcSEcCtD
Loratadine—Alopecia—Epirubicin—urinary bladder cancer	0.000356	0.00163	CcSEcCtD
Loratadine—Nausea—Gemcitabine—urinary bladder cancer	0.000356	0.00163	CcSEcCtD
Loratadine—Vomiting—Cisplatin—urinary bladder cancer	0.000355	0.00163	CcSEcCtD
Loratadine—Rash—Cisplatin—urinary bladder cancer	0.000352	0.00161	CcSEcCtD
Loratadine—Dermatitis—Cisplatin—urinary bladder cancer	0.000352	0.00161	CcSEcCtD
Loratadine—Diarrhoea—Etoposide—urinary bladder cancer	0.00035	0.0016	CcSEcCtD
Loratadine—Nausea—Fluorouracil—urinary bladder cancer	0.00035	0.0016	CcSEcCtD
Loratadine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000348	0.0016	CcSEcCtD
Loratadine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000348	0.00159	CcSEcCtD
Loratadine—Tension—Epirubicin—urinary bladder cancer	0.000345	0.00158	CcSEcCtD
Loratadine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000344	0.00158	CcSEcCtD
Loratadine—Nervousness—Epirubicin—urinary bladder cancer	0.000341	0.00156	CcSEcCtD
Loratadine—Malaise—Methotrexate—urinary bladder cancer	0.000338	0.00155	CcSEcCtD
Loratadine—Dizziness—Etoposide—urinary bladder cancer	0.000338	0.00155	CcSEcCtD
Loratadine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000337	0.00155	CcSEcCtD
Loratadine—ABCB1—lymph node—urinary bladder cancer	0.000336	0.00606	CbGeAlD
Loratadine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000333	0.00153	CcSEcCtD
Loratadine—Nausea—Cisplatin—urinary bladder cancer	0.000332	0.00152	CcSEcCtD
Loratadine—Alopecia—Doxorubicin—urinary bladder cancer	0.00033	0.00151	CcSEcCtD
Loratadine—Cough—Methotrexate—urinary bladder cancer	0.000327	0.0015	CcSEcCtD
Loratadine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000326	0.00149	CcSEcCtD
Loratadine—Vomiting—Etoposide—urinary bladder cancer	0.000325	0.00149	CcSEcCtD
Loratadine—Agitation—Epirubicin—urinary bladder cancer	0.000323	0.00148	CcSEcCtD
Loratadine—Rash—Etoposide—urinary bladder cancer	0.000322	0.00148	CcSEcCtD
Loratadine—Dermatitis—Etoposide—urinary bladder cancer	0.000322	0.00148	CcSEcCtD
Loratadine—Headache—Etoposide—urinary bladder cancer	0.00032	0.00147	CcSEcCtD
Loratadine—Myalgia—Methotrexate—urinary bladder cancer	0.000319	0.00146	CcSEcCtD
Loratadine—Chest pain—Methotrexate—urinary bladder cancer	0.000319	0.00146	CcSEcCtD
Loratadine—Tension—Doxorubicin—urinary bladder cancer	0.000319	0.00146	CcSEcCtD
Loratadine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000318	0.00146	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000317	0.00145	CcSEcCtD
Loratadine—Malaise—Epirubicin—urinary bladder cancer	0.000317	0.00145	CcSEcCtD
Loratadine—Discomfort—Methotrexate—urinary bladder cancer	0.000316	0.00145	CcSEcCtD
Loratadine—Nervousness—Doxorubicin—urinary bladder cancer	0.000316	0.00145	CcSEcCtD
Loratadine—Syncope—Epirubicin—urinary bladder cancer	0.000315	0.00144	CcSEcCtD
Loratadine—Palpitations—Epirubicin—urinary bladder cancer	0.00031	0.00142	CcSEcCtD
Loratadine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000309	0.00141	CcSEcCtD
Loratadine—Cough—Epirubicin—urinary bladder cancer	0.000306	0.0014	CcSEcCtD
Loratadine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000306	0.0014	CcSEcCtD
Loratadine—Nausea—Etoposide—urinary bladder cancer	0.000304	0.00139	CcSEcCtD
Loratadine—Hypertension—Epirubicin—urinary bladder cancer	0.000303	0.00139	CcSEcCtD
Loratadine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000301	0.00138	CcSEcCtD
Loratadine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.0003	0.00138	CcSEcCtD
Loratadine—Myalgia—Epirubicin—urinary bladder cancer	0.000299	0.00137	CcSEcCtD
Loratadine—Chest pain—Epirubicin—urinary bladder cancer	0.000299	0.00137	CcSEcCtD
Loratadine—Agitation—Doxorubicin—urinary bladder cancer	0.000299	0.00137	CcSEcCtD
Loratadine—Skin disorder—Methotrexate—urinary bladder cancer	0.000297	0.00136	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000297	0.00136	CcSEcCtD
Loratadine—Discomfort—Epirubicin—urinary bladder cancer	0.000295	0.00135	CcSEcCtD
Loratadine—Malaise—Doxorubicin—urinary bladder cancer	0.000293	0.00134	CcSEcCtD
Loratadine—Dry mouth—Epirubicin—urinary bladder cancer	0.000292	0.00134	CcSEcCtD
Loratadine—Syncope—Doxorubicin—urinary bladder cancer	0.000291	0.00134	CcSEcCtD
Loratadine—Palpitations—Doxorubicin—urinary bladder cancer	0.000287	0.00132	CcSEcCtD
Loratadine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000287	0.00131	CcSEcCtD
Loratadine—Hypotension—Methotrexate—urinary bladder cancer	0.000286	0.00131	CcSEcCtD
Loratadine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000286	0.00131	CcSEcCtD
Loratadine—Cough—Doxorubicin—urinary bladder cancer	0.000284	0.0013	CcSEcCtD
Loratadine—Shock—Epirubicin—urinary bladder cancer	0.000282	0.00129	CcSEcCtD
Loratadine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000281	0.00129	CcSEcCtD
Loratadine—Hypertension—Doxorubicin—urinary bladder cancer	0.000281	0.00129	CcSEcCtD
Loratadine—Tachycardia—Epirubicin—urinary bladder cancer	0.00028	0.00128	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000279	0.00128	CcSEcCtD
Loratadine—Skin disorder—Epirubicin—urinary bladder cancer	0.000278	0.00128	CcSEcCtD
Loratadine—Insomnia—Methotrexate—urinary bladder cancer	0.000277	0.00127	CcSEcCtD
Loratadine—Chest pain—Doxorubicin—urinary bladder cancer	0.000277	0.00127	CcSEcCtD
Loratadine—Myalgia—Doxorubicin—urinary bladder cancer	0.000277	0.00127	CcSEcCtD
Loratadine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000275	0.00126	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000275	0.00126	CcSEcCtD
Loratadine—Discomfort—Doxorubicin—urinary bladder cancer	0.000273	0.00125	CcSEcCtD
Loratadine—Somnolence—Methotrexate—urinary bladder cancer	0.000272	0.00125	CcSEcCtD
Loratadine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000271	0.00124	CcSEcCtD
Loratadine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00027	0.00124	CcSEcCtD
Loratadine—Hypotension—Epirubicin—urinary bladder cancer	0.000268	0.00123	CcSEcCtD
Loratadine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000265	0.00122	CcSEcCtD
Loratadine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000264	0.00121	CcSEcCtD
Loratadine—Fatigue—Methotrexate—urinary bladder cancer	0.000264	0.00121	CcSEcCtD
Loratadine—Pain—Methotrexate—urinary bladder cancer	0.000262	0.0012	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000261	0.0012	CcSEcCtD
Loratadine—Shock—Doxorubicin—urinary bladder cancer	0.000261	0.0012	CcSEcCtD
Loratadine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00026	0.00119	CcSEcCtD
Loratadine—Insomnia—Epirubicin—urinary bladder cancer	0.000259	0.00119	CcSEcCtD
Loratadine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000259	0.00119	CcSEcCtD
Loratadine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000258	0.00118	CcSEcCtD
Loratadine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000257	0.00118	CcSEcCtD
Loratadine—Somnolence—Epirubicin—urinary bladder cancer	0.000255	0.00117	CcSEcCtD
Loratadine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000252	0.00116	CcSEcCtD
Loratadine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000252	0.00116	CcSEcCtD
Loratadine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00025	0.00115	CcSEcCtD
Loratadine—Hypotension—Doxorubicin—urinary bladder cancer	0.000248	0.00114	CcSEcCtD
Loratadine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000247	0.00113	CcSEcCtD
Loratadine—Fatigue—Epirubicin—urinary bladder cancer	0.000247	0.00113	CcSEcCtD
Loratadine—Constipation—Epirubicin—urinary bladder cancer	0.000245	0.00112	CcSEcCtD
Loratadine—Pain—Epirubicin—urinary bladder cancer	0.000245	0.00112	CcSEcCtD
Loratadine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000242	0.00111	CcSEcCtD
Loratadine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000242	0.00111	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000242	0.00111	CcSEcCtD
Loratadine—Insomnia—Doxorubicin—urinary bladder cancer	0.00024	0.0011	CcSEcCtD
Loratadine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000238	0.00109	CcSEcCtD
Loratadine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000236	0.00108	CcSEcCtD
Loratadine—Somnolence—Doxorubicin—urinary bladder cancer	0.000236	0.00108	CcSEcCtD
Loratadine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000234	0.00107	CcSEcCtD
Loratadine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000233	0.00107	CcSEcCtD
Loratadine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000229	0.00105	CcSEcCtD
Loratadine—Fatigue—Doxorubicin—urinary bladder cancer	0.000229	0.00105	CcSEcCtD
Loratadine—Constipation—Doxorubicin—urinary bladder cancer	0.000227	0.00104	CcSEcCtD
Loratadine—Pain—Doxorubicin—urinary bladder cancer	0.000227	0.00104	CcSEcCtD
Loratadine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000227	0.00104	CcSEcCtD
Loratadine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000227	0.00104	CcSEcCtD
Loratadine—Asthenia—Methotrexate—urinary bladder cancer	0.00022	0.00101	CcSEcCtD
Loratadine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000219	0.001	CcSEcCtD
Loratadine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000217	0.000994	CcSEcCtD
Loratadine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.00021	0.000961	CcSEcCtD
Loratadine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00021	0.000961	CcSEcCtD
Loratadine—Diarrhoea—Methotrexate—urinary bladder cancer	0.00021	0.00096	CcSEcCtD
Loratadine—Asthenia—Epirubicin—urinary bladder cancer	0.000206	0.000942	CcSEcCtD
Loratadine—Dizziness—Methotrexate—urinary bladder cancer	0.000203	0.000928	CcSEcCtD
Loratadine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000196	0.000899	CcSEcCtD
Loratadine—Vomiting—Methotrexate—urinary bladder cancer	0.000195	0.000892	CcSEcCtD
Loratadine—Rash—Methotrexate—urinary bladder cancer	0.000193	0.000885	CcSEcCtD
Loratadine—Dermatitis—Methotrexate—urinary bladder cancer	0.000193	0.000884	CcSEcCtD
Loratadine—Headache—Methotrexate—urinary bladder cancer	0.000192	0.000879	CcSEcCtD
Loratadine—Asthenia—Doxorubicin—urinary bladder cancer	0.00019	0.000872	CcSEcCtD
Loratadine—Dizziness—Epirubicin—urinary bladder cancer	0.00019	0.000869	CcSEcCtD
Loratadine—Vomiting—Epirubicin—urinary bladder cancer	0.000182	0.000835	CcSEcCtD
Loratadine—Nausea—Methotrexate—urinary bladder cancer	0.000182	0.000834	CcSEcCtD
Loratadine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000181	0.000832	CcSEcCtD
Loratadine—Rash—Epirubicin—urinary bladder cancer	0.000181	0.000828	CcSEcCtD
Loratadine—Dermatitis—Epirubicin—urinary bladder cancer	0.000181	0.000827	CcSEcCtD
Loratadine—Headache—Epirubicin—urinary bladder cancer	0.00018	0.000823	CcSEcCtD
Loratadine—Dizziness—Doxorubicin—urinary bladder cancer	0.000175	0.000804	CcSEcCtD
Loratadine—Nausea—Epirubicin—urinary bladder cancer	0.00017	0.00078	CcSEcCtD
Loratadine—Vomiting—Doxorubicin—urinary bladder cancer	0.000169	0.000773	CcSEcCtD
Loratadine—Rash—Doxorubicin—urinary bladder cancer	0.000167	0.000766	CcSEcCtD
Loratadine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000167	0.000766	CcSEcCtD
Loratadine—Headache—Doxorubicin—urinary bladder cancer	0.000166	0.000761	CcSEcCtD
Loratadine—Nausea—Doxorubicin—urinary bladder cancer	0.000158	0.000722	CcSEcCtD
Loratadine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.87e-05	0.00104	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.79e-05	0.00103	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.86e-05	0.000926	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.59e-05	0.000893	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	7.3e-05	0.000859	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.95e-05	0.000818	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.92e-05	0.000815	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	6.92e-05	0.000815	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NAT1—urinary bladder cancer	6.92e-05	0.000815	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.89e-05	0.000811	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.81e-05	0.000801	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	6.77e-05	0.000797	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	6.52e-05	0.000767	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.4e-05	0.000753	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	6.36e-05	0.000749	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	6.33e-05	0.000745	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.31e-05	0.000743	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NAT1—urinary bladder cancer	6.18e-05	0.000727	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	6.18e-05	0.000727	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—HRAS—urinary bladder cancer	6.1e-05	0.000718	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.08e-05	0.000715	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.04e-05	0.000711	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	6.03e-05	0.00071	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NAT1—urinary bladder cancer	6.03e-05	0.00071	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	5.99e-05	0.000706	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.96e-05	0.000702	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.94e-05	0.000699	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.88e-05	0.000692	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.8e-05	0.000683	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HDAC4—urinary bladder cancer	5.78e-05	0.000681	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	5.7e-05	0.000671	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.68e-05	0.000669	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.68e-05	0.000669	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	5.65e-05	0.000665	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.63e-05	0.000663	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.63e-05	0.000663	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.54e-05	0.000652	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.51e-05	0.000649	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	5.38e-05	0.000634	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	5.24e-05	0.000617	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	5.2e-05	0.000612	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.15e-05	0.000606	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	5.12e-05	0.000603	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.12e-05	0.000603	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	5.09e-05	0.000599	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	5.06e-05	0.000596	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.06e-05	0.000596	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.96e-05	0.000585	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.95e-05	0.000582	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—GLI1—urinary bladder cancer	4.84e-05	0.00057	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	4.8e-05	0.000566	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	4.78e-05	0.000563	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.69e-05	0.000552	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	4.68e-05	0.000551	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.68e-05	0.000551	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.64e-05	0.000546	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.57e-05	0.000538	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.47e-05	0.000526	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.42e-05	0.00052	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.38e-05	0.000516	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.32e-05	0.000509	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.31e-05	0.000508	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	4.31e-05	0.000507	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.27e-05	0.000503	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.21e-05	0.000495	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—TYMP—urinary bladder cancer	4.19e-05	0.000494	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.11e-05	0.000484	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.06e-05	0.000478	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.03e-05	0.000474	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4e-05	0.000471	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.92e-05	0.000461	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.9e-05	0.000459	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NAT2—urinary bladder cancer	3.79e-05	0.000446	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.75e-05	0.000442	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	3.74e-05	0.000441	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.71e-05	0.000437	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.71e-05	0.000437	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.65e-05	0.00043	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.59e-05	0.000423	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.58e-05	0.000422	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.51e-05	0.000413	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.44e-05	0.000405	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.42e-05	0.000403	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.41e-05	0.000402	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.4e-05	0.0004	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.38e-05	0.000398	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.34e-05	0.000393	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	3.32e-05	0.000391	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.31e-05	0.00039	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.3e-05	0.000389	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.28e-05	0.000386	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	3.27e-05	0.000385	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	3.12e-05	0.000368	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.11e-05	0.000367	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.09e-05	0.000363	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.06e-05	0.00036	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	3.03e-05	0.000357	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	3.03e-05	0.000357	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.01e-05	0.000355	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	2.97e-05	0.00035	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.94e-05	0.000347	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.94e-05	0.000346	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.92e-05	0.000344	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.89e-05	0.000341	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.89e-05	0.00034	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.85e-05	0.000336	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.82e-05	0.000331	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.71e-05	0.000319	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.71e-05	0.000319	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.69e-05	0.000317	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.69e-05	0.000316	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.66e-05	0.000314	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.64e-05	0.000311	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.64e-05	0.000311	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.62e-05	0.000309	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.58e-05	0.000304	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.56e-05	0.000302	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	2.51e-05	0.000296	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.49e-05	0.000293	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.49e-05	0.000293	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.47e-05	0.00029	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.47e-05	0.00029	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.45e-05	0.000289	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.44e-05	0.000288	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.41e-05	0.000284	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	2.41e-05	0.000283	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.4e-05	0.000282	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.39e-05	0.000282	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.37e-05	0.000279	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.36e-05	0.000277	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	2.28e-05	0.000269	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.25e-05	0.000265	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.21e-05	0.00026	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.18e-05	0.000257	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	2.16e-05	0.000255	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.13e-05	0.000251	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.12e-05	0.000249	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	2.11e-05	0.000248	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.07e-05	0.000243	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.04e-05	0.00024	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.04e-05	0.00024	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.01e-05	0.000236	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	2e-05	0.000236	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.99e-05	0.000234	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.97e-05	0.000232	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.93e-05	0.000227	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	1.91e-05	0.000225	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	1.91e-05	0.000225	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.89e-05	0.000223	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.87e-05	0.00022	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.87e-05	0.00022	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.85e-05	0.000217	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.82e-05	0.000214	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.79e-05	0.000211	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.78e-05	0.000209	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.76e-05	0.000207	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.76e-05	0.000207	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.76e-05	0.000207	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	1.75e-05	0.000206	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	1.7e-05	0.0002	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.69e-05	0.000199	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.68e-05	0.000198	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.67e-05	0.000197	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.67e-05	0.000197	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.67e-05	0.000197	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.66e-05	0.000195	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.66e-05	0.000195	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.65e-05	0.000194	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.63e-05	0.000192	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.63e-05	0.000192	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.63e-05	0.000192	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.63e-05	0.000192	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.6e-05	0.000189	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.6e-05	0.000188	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.58e-05	0.000186	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	0.000185	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.56e-05	0.000184	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.56e-05	0.000183	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.54e-05	0.000182	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.54e-05	0.000181	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.54e-05	0.000181	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.53e-05	0.000181	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.52e-05	0.000179	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.52e-05	0.000179	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.49e-05	0.000175	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.48e-05	0.000174	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.47e-05	0.000173	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.47e-05	0.000173	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.46e-05	0.000172	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.46e-05	0.000172	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.45e-05	0.00017	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.44e-05	0.00017	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.43e-05	0.000169	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.38e-05	0.000163	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.36e-05	0.00016	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.35e-05	0.000159	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.35e-05	0.000159	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.34e-05	0.000158	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.31e-05	0.000154	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.29e-05	0.000152	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.25e-05	0.000147	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.2e-05	0.000141	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-05	0.000139	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.18e-05	0.000138	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.17e-05	0.000138	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	0.000135	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.13e-05	0.000133	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.12e-05	0.000132	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-05	0.00013	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.1e-05	0.00013	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.09e-05	0.000129	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.09e-05	0.000129	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	0.000126	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	0.000126	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	0.000125	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.06e-05	0.000125	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.06e-05	0.000124	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.05e-05	0.000124	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.02e-05	0.00012	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	0.000119	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.01e-05	0.000118	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.01e-05	0.000118	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	9.87e-06	0.000116	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.63e-06	0.000113	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.45e-06	0.000111	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	9.42e-06	0.000111	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	9.21e-06	0.000108	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	9.2e-06	0.000108	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.88e-06	0.000105	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	8.84e-06	0.000104	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—EP300—urinary bladder cancer	8.78e-06	0.000103	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	8.67e-06	0.000102	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	8.65e-06	0.000102	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.59e-06	0.000101	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	8.22e-06	9.68e-05	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	8.17e-06	9.62e-05	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.02e-06	9.44e-05	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—EP300—urinary bladder cancer	7.84e-06	9.23e-05	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—EP300—urinary bladder cancer	7.65e-06	9.01e-05	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	7.56e-06	8.9e-05	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.49e-06	8.82e-05	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	7.26e-06	8.55e-05	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—EP300—urinary bladder cancer	7.21e-06	8.49e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.2e-06	8.48e-05	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.15e-06	8.41e-05	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	6.94e-06	8.18e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.92e-06	8.15e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.67e-06	6.67e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.94e-06	5.82e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.71e-06	5.55e-05	CbGpPWpGaD
